A number of other equities analysts have also commented on the stock. Piper Jaffray Companies reaffirmed a positive rating and issued a $9.00 price objective (up previously from $7.00) on shares of Kadmon in a research note on Tuesday, February 13th. Jefferies Group raised their price objective on shares of Kadmon to $16.00 and gave the stock a buy rating in a research note on Tuesday, February 13th. Finally, Zacks Investment Research lowered shares of Kadmon from a hold rating to a sell rating in a research note on Wednesday, January 31st. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the stock. The stock currently has an average rating of Hold and a consensus price target of $10.21.
Kadmon (NYSE:KDMN) opened at $4.29 on Friday. Kadmon has a 52 week low of $2.05 and a 52 week high of $5.86. The company has a market cap of $337.38 and a P/E ratio of -2.88.
Large investors have recently modified their holdings of the business. Crestline Management LP acquired a new stake in shares of Kadmon during the 3rd quarter valued at $2,011,000. Wells Fargo & Company MN boosted its stake in shares of Kadmon by 23.2% during the 3rd quarter. Wells Fargo & Company MN now owns 73,956 shares of the company’s stock valued at $247,000 after buying an additional 13,923 shares during the period. AE Wealth Management LLC boosted its stake in shares of Kadmon by 61.1% during the 4th quarter. AE Wealth Management LLC now owns 520,713 shares of the company’s stock valued at $1,885,000 after buying an additional 197,552 shares during the period. Sphera Funds Management LTD. acquired a new stake in shares of Kadmon during the 3rd quarter valued at $3,685,000. Finally, Vanguard Group Inc. boosted its stake in shares of Kadmon by 166.0% during the 2nd quarter. Vanguard Group Inc. now owns 1,508,869 shares of the company’s stock valued at $5,870,000 after buying an additional 941,549 shares during the period. 61.71% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “Kadmon’s (KDMN) “Buy” Rating Reaffirmed at HC Wainwright” was published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.themarketsdaily.com/2018/03/13/kadmons-kdmn-buy-rating-reaffirmed-at-hc-wainwright.html.
Kadmon Company Profile
Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.